Health Care

Recordati’s latest share‑buyback and VAZKEPA® partnership boost investor value and position the company for growth in Europe’s cardiovascular market.

Solventum Corp’s Q4 2025 earnings show a 19.4 % profit jump and 3.8 % organic growth, driven by cost cuts and a new share‑buyback, hinting at strong 2026 momentum.

Discover how Astellas and Vir Biotechnology’s global partnership for VIR‑5500 could transform prostate‑cancer treatment, blending advanced immunotherapy with strategic market‑access plans.

How Eli Lilly battles Novo Nordisk’s price cuts: portfolio tweaks, pipeline pushes and global moves keep the pharma titan poised for tomorrow’s market shifts.

Argenx SE investor update: upcoming Q4 earnings reveal pipeline progress, regulatory milestones, and commercial strategy for autoimmune and oncology antibody therapies.

Elevance Health’s new CTO and “Food as Medicine” expansion show how tech-driven engagement and preventive care can cut costs, boost value‑based outcomes, and win members in a shifting US health market.

Merck’s split of its pharma division targets the Keytruda patent cliff by focusing new growth on vaccines and lung‑disease therapies, boosting investor clarity and future revenue.

Galderma’s new Restylane syringe earns EU, US, and Canadian clearance, offering ergonomic design, proven safety, and improved patient comfort for facial and hand treatments.

Terumo Corporation maintains a steady position amid rising global demand for advanced medical devices, leveraging a diversified portfolio, strong distribution network, and robust R&D to capture growth in key segments while staying compliant and …

Explore how IDEXX Laboratories thrives amid market swings, leveraging digital diagnostics, regulatory demand, and diversification across veterinary, food, and water testing.